Clinical Trials · NCT04262154
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 28
- Start date
- Mar 2020
- Locations
- 8 sites, United States
- Primary endpoint
- Failure-free Rate at 2 Years